Clinical trial · Observational
Genetic Variants and Chemotherapy-induced Abnormal Thermal Sensation
To Study the Individual Variants of Chemotherapy-induced Abnormal Thermal Sensation in Cancer Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Poor enrollment
Summary
Brief summary (as posted)
This is a prospective, single arm, single center study evaluating the use of a 4-gene panel to predict the occurrence of chemotherapy-induced abnormal thermal threshold in endometrial and ovarian cancer patients receiving post-operative chemotherapy with Carboplatin/Paclitaxel, and stage III colorectal cancer patients receiving adjuvant chemotherapy with mFOLFOX6. A total of 100 patients will be enrolled during 2017 July\~ 2019 June. Blood sample will be collected before chemotherapy to analyze the genetic variants of TRPV1, TRPM2, TRPA1 and ORAI1. All patients will receive neurologic examination (Quantitative Sensory Test, QST) and complete the questionnaires for quality of life (EQ5D \& CIPN20). The primary endpoint of this study is to test if the genetic variant of TRPV1, TRPM2, TRPA1, and ORAI1 is a predictive biomarker for the chemotherapy-induced abnormal thermal sensation in cancer patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chemotherapy-induced Abnormal Thermal Sensation | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Genetic variants of TRPV1, TRPM2, TRPA1 and ORAI | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Patients with endometrial or ovarian cancer
- interventionNames
- Diagnostic Test: Genetic variants of TRPV1, TRPM2, TRPA1 and ORAI
- label
- Patients with colorectal cancer
- interventionNames
- Diagnostic Test: Genetic variants of TRPV1, TRPM2, TRPA1 and ORAI
Primary outcomes (1)
- measure
- The change of thermal pain threshold
- timeFrame
- before chemotherapy & 3, 6, and 9 months after chemotherapy
- description
- The threshold of detecting heat-induced pain
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 20 years old * Pathological stage I\~IV for ovarian cancer, stage II\~IV for endometrial cancer, or stage III for colorectal cancer. * Scheduled to receive adjuvant Paclitaxel/Carboplatin for ovarian or endometrial cancer, or mFOLFOX6 for colorectal cancer. * Patient willing to provide blood sample for research purposes. * Ability of the patient to provide informed consent. Exclusion Criteria: * Prior treatment with neurotoxic chemotherapy, such as oxaliplatin, cisplatin, carboplatin, taxanes or vinca alkaloids. * Receiving chemotherapy within 6 months. * A family history of a genetic or familial neuropathy * Poor compliance
References
Publications (1)
- DERIVEDChubanov V, Grimm C, Hill K, Schaefer M, Kottgen M, Storch U, Mederos Y Schnitzler M, Kudrina V, Erbacher A, Gudermann T. Physiological functions and pharmacological targeting of transient receptor potential channels. Pharmacol Rev. 2025 Nov;77(6):100089. doi: 10.1016/j.pharmr.2025.100089. Epub 2025 Sep 13. PMID 41118703